ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print

Daiichi Sankyo pours $13bn into new cancer treatments

Drugmaker to build on Enhertu success under new five-year plan

Daiichi Sankyo had named cancer treatment as one of its main focus areas in 2016. (Photo from Daiichi Sankyo U.S. Twitter account)

TOKYO -- Japanese drugmaker Daiichi Sankyo will spend 1.5 trillion yen ($13.6 billion) on new cancer treatments under its five-year plan through March 2026, accelerating its push to develop potential blockbuster drugs.

"We are making great headway in our cancer business," President and CEO Sunao Manabe said at an online news conference Monday to announce the new plan. "We are on the path to becoming a global drug developer with an edge in cancer treatments."

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more